Regenerex licenses stem cell technology to Novartis

09/8/2013 | Bloomberg

Novartis has secured the exclusive global rights to use Regenerex's stem cell technology, which has potential applications in oncology, transplantation and metabolic disorders. The firms will collaborate on research as part of the deal. A study published last year showed the stem cell technology allowed five of eight kidney transplant recipients to stop taking about a dozen daily anti-rejection pills.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT